Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

UCITS HFS Index experiences third monthly loss in a row, down -0.70% in May 2012

Monday, June 11, 2012
Opalesque Industry Update - The UCITS HFS Index continues its downward trend with a setback of -0.70% in May 2012 after its drop of -0.36% and -0.34% in April and March respectively. The largest part of the May loss is attributable to the first two weeks of trading in which the UCITS HFS Index took losses of -0.45% and -0.37%. The third week had less impact, still being negative though (-0.17%). Similar to most of the sub-strategies the UCITS HFS managed to have a positive performance during the last week of May with gains +0.28%, slightly softening the monthly loss.

From a sub-strategy perspective five out of the twelve sub-strategies returned profits in May. The best performing strategies were CTA (+2.11%) and Currency (+1.75%), both of which had been negative in March and April. CTA lost -0.72% during the first week of trading, however, managed to cut the losses over the three following weeks, in particular with a performance of +1.98% during the last week of May. On the other hand, Currency managed to post positive returns week after week throughout May. Credit and Fixed Income are the only two strategies with back to back positive monthly results in 2012, accumulating now six positive months. They stand at +3.48% and +2.59% in 2012. The three worst performing strategies in May were L/S Equity (-2.23%), Commodity (-2.14%) and Convertible (-0.78%). While L/S Equity and Commodity managed to earn money during the last week of May, Convertible was negative throughout the whole month. From a year to date perspective the broad UCITS HFS Index now stands at +1.11% in 2012.

Press Release

BC

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for